Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma

Published:2015-03-17 Issue:6 Volume:101 Page:585-593
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Kurita Daisuke,Miura Katsuhiro,Nakagawa Masaru,Ohtake Shimon,Sakagami Masashi,Uchino Yoshihito,Takahashi Hiromichi,Kiso Satomi,Hojo Atsuko,Kodaira Hitomi,Yagi Mai,Hirabayashi Yukio,Kobayashi Yujin,Iriyama Noriyoshi,Kobayashi Sumiko,Hatta Yoshihiro,Kura Yoshimasa,Sugitani Masahiko,Takei Masami

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-015-1780-6.pdf

Reference27 articles.

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.

3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

4. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

5. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis;Leukemia;2023-12-29

2. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma;Expert Review of Anticancer Therapy;2022-05-05

3. Malignant Lymphoma:;Journal of Nihon University Medical Association;2022-04-01

4. Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience;eJHaem;2022-02-02

5. An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma;Frontiers in Oncology;2019-09-04